Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients-Reference-Cited by-同舟云学术

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

Published:2022-04 Issue:4 Volume:40 Page:335-337
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Canti Lorenzo,Ariën Kevin K.,Desombere Isabelle,Humblet-Baron Stéphanie,Pannus Pieter,Heyndrickx Leo,Henry Aurélie,Servais Sophie,Willems Evelyne,Ehx Grégory,Goriely Stanislas,Seidel Laurence,Michiels Johan,Willems Betty,Goossens Maria E.,Beguin Yves,Marchant Arnaud,Baron Frédéric

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference10 articles.

1. Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern;Ariën;Preprint at MedRxiv,2021

2. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients;Canti;J. Hematol. Oncol.,2021

3. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant;Gruell;Nat. Med.,2022

4. Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients;Jurdi;MedRxiv,2022

5. Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant;Le Bourgeois;Br. J. Haematol.,2021

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis;Virology Journal;2024-05-03

2. COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy;Transplant Infectious Disease;2023-09-28

3. Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients;Leukemia & Lymphoma;2023-08-13

4. Longitudinal data on humoral response and neutralizing antibodies against SARS-CoV-2 Omicron BA.1 and subvariants BA.4/5 and BQ.1.1 after COVID-19 vaccination in cancer patients;Journal of Cancer Research and Clinical Oncology;2023-06-10

5. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study;Frontiers in Immunology;2023-04-19